Meet the “Bliss Molecule” Your Brain Already Makes (and Why Migraine Sufferers May Be Running Low)
Pop quiz, and I promise this is the only one all article. Somewhere in your brain, right now, a molecule is quietly doing its job: modulating your mood, dulling unnecessary pain, nudging your appetite, deciding whether that stressful email deserves the full body cortisol spiral or a shrug. It was discovered less than a lifetime ago, hiding in a pig’s brain, and when the scientists who found it needed a name, they reached for Sanskrit instead of Latin. They called it ananda, meaning bliss.
Say hello to anandamide. If cannabis has a secret twin already living inside you, this is it. And it turns out that for people who suffer from migraines, understanding this molecule might be the single most illuminating thing you learn about your condition all year. Let’s get into it.
The Discovery: A Pig Brain and a Sanskrit Word
In 1992, a research team at Hebrew University in Jerusalem, made up of Raphael Mechoulam, William Devane, and Lumír Hanuš, went looking for something that had been nagging scientists for decades. Researchers had already mapped cannabinoid receptors sitting on cells throughout the human brain and body. But that raised an obvious, slightly embarrassing question: why would the human body evolve a lock that only a plant’s key seemed to fit? Surely we weren’t building elaborate receptor systems purely in anticipation of cannabis.
The team isolated a compound from pig brain tissue that bound to those very receptors: our own, homegrown, endogenous cannabinoid. When it came time to name it, the discoverers turned to the Sanskrit word “ananda,” meaning joy or bliss, deliberately coining the term from that root combined with the compound’s chemical class (1*). Anandamide was born, chemistry with a poet’s signature.
Fun fact for your next dinner party: that “runner’s high” you’ve heard about for years, the one everyone used to credit to endorphins? A 2003 study found that moderate intensity exercise activates the endocannabinoid system and elevates anandamide levels, and the researchers concluded anandamide, not endorphins, is the more likely source of that post run euphoria, since endorphins are too large to cross the blood brain barrier from where they’re released, while anandamide is not (2*). That glow after a long walk on the beach? That’s your own internal cannabis system, quietly at work.
The Plot Twist: What Happens When the Bliss Runs Low
Here’s where this gets genuinely useful if you or someone you love deals with migraines. In 2004, and again in a more rigorous 2016 follow up, neurologist and cannabinoid researcher Dr. Ethan Russo proposed something called Clinical Endocannabinoid Deficiency, or CECD, a theory built on a deceptively simple idea. If the endocannabinoid system’s job is to regulate pain sensitivity, gut function, mood, and sleep, what happens to a person whose baseline levels of anandamide are simply too low to do that job properly?
Russo’s review concluded that migraine, fibromyalgia, and irritable bowel syndrome share a striking amount of clinical overlap. They cluster in the same patients, resist the same conventional treatments, and involve the same signature of heightened pain sensitivity, and Russo proposed that an underlying deficiency in endocannabinoid tone could be the unifying thread connecting all three (3*). It’s not a fringe idea anymore. It’s one of the more compelling working theories in headache medicine today.
The Receipts: What Migraine Brains Actually Show
Theories are cheap; data is what convinces a professor. So here’s the part that matters: when researchers have actually gone looking for anandamide in migraine patients, they’ve found it missing. Studies measuring endocannabinoid levels in the cerebrospinal fluid of chronic migraine sufferers found significantly lower anandamide compared with headache free controls (4*), not a subtle trend, but a measurable deficit, sitting right there in the spinal fluid of people whose heads are throbbing.
Why would that matter mechanistically? Migraine pain runs largely along the trigeminal nerve pathway, and CB1 receptors, anandamide’s primary docking site, are densely packed along exactly that route, including the trigeminal nucleus and the periaqueductal gray, a key pain modulating structure in the brainstem (5*). Activating those receptors appears to inhibit the release of a peptide called CGRP, calcitonin gene related peptide, the very same molecule that the newest, most expensive class of prescription migraine medications on the market was built specifically to block (5*). In other words, your endocannabinoid system and your costly migraine injection may be aiming at the same target. One of them, evolution built for free.
So Does Cannabis Actually Help Migraines? The Honest Answer
Yes, with real, growing clinical evidence, though not yet at the rock solid “conclusive” tier reserved for chronic pain broadly. A 2022 review pooling 12 published studies and nearly 2,000 participants found that medical cannabis use was associated with meaningful reductions in migraine frequency, and specifically significantly reduced the nausea and vomiting that so often accompanies migraine attacks after six months of use (6*). Separate real world data drawn from patient tracking apps found that inhaled cannabis cut self reported headache and migraine pain by roughly half in the moment of an attack.
The two main players do different jobs, and this is worth understanding before you’d ever try either one: THC is the more thoroughly studied compound for migraine and produces strong analgesic and anti nausea effects, making it particularly useful during an acute attack, while CBD is non intoxicating and is of more interest for its anti inflammatory and neuroprotective properties (7*), though the evidence for CBD alone treating migraine directly is still thinner than for THC or combination products.
The Fine Print
I’d be a poor lecturer if I let you leave without the caveats, because they matter. Frequent, heavy cannabis use can occasionally cause a rebound headache pattern of its own, the same overuse phenomenon seen with many other pain medications, and in susceptible individuals, very heavy chronic use has been linked to cannabinoid hyperemesis syndrome, a distinct nausea and vomiting condition unrelated to migraine itself. The right approach, as with most things in this field, is starting low, going slow, and working with a physician who can help you find a ratio and routine suited to your body rather than guessing.
The Closing
What I find genuinely delightful about this whole story is the shape of it: a molecule named after joy, discovered by accident in a pig’s brain, that may turn out to explain why some of the most stubborn, “it’s all in your head” pain conditions in medicine are not imaginary at all. They may simply be a body running short on its own internal bliss. Cannabis, in that light, isn’t introducing something foreign to your physiology. For a meaningful subset of migraine patients, it may be topping off a tank that was already running low.
Go easy on yourself, hydrate, and give your endocannabinoid system a little credit this week.
References
(1*) Devane WA, Hanuš L, Breuer A, et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science. 1992;258(5090):1946-1949.
(2*) Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. NeuroReport. 2003.
(3*) Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165.
(4*) Sarchielli P, et al. Endocannabinoid levels in cerebrospinal fluid of chronic migraine patients. Neuropsychopharmacology. 2007 (as summarized in Russo, 2016, and subsequent reviews).
(5*) Cannabis and Migraines: What Patients Are Finding and What the Research Shows. Review of CB1 receptor distribution (trigeminal nucleus, periaqueductal gray) and CGRP mechanism.
(6*) Okusanya BO, et al. Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence. 2022.
(7*) Association of Cannabinoid Specialists. Cannabinoids and Migraines: Emerging Evidence and Clinical Implications. Review of THC and CBD differentiated roles in migraine treatment.
This article is for general education and is not a substitute for professional medical advice. If migraines are a regular part of your life, REN Health’s physicians can help you explore whether medical cannabis is an appropriate, evidence informed part of your treatment plan.
